These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 17988876)

  • 1. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
    Taha MO; Atallah N; Al-Bakri AG; Paradis-Bleau C; Zalloum H; Younis KS; Levesque RC
    Bioorg Med Chem; 2008 Feb; 16(3):1218-35. PubMed ID: 17988876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
    Al-Masri IM; Mohammad MK; Taha MO
    ChemMedChem; 2008 Nov; 3(11):1763-79. PubMed ID: 18989859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
    Taha MO; Dahabiyeh LA; Bustanji Y; Zalloum H; Saleh S
    J Med Chem; 2008 Oct; 51(20):6478-94. PubMed ID: 18808096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.
    Taha MO; Tarairah M; Zalloum H; Abu-Sheikha G
    J Mol Graph Model; 2010 Jan; 28(5):383-400. PubMed ID: 19850503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
    Abu Hammad AM; Taha MO
    J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
    Al-Nadaf AH; Taha MO
    J Mol Graph Model; 2011 Apr; 29(6):843-64. PubMed ID: 21376648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.
    Taha MO; Bustanji Y; Al-Bakri AG; Yousef AM; Zalloum WA; Al-Masri IM; Atallah N
    J Mol Graph Model; 2007 Mar; 25(6):870-84. PubMed ID: 17035054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors.
    Al-Sha'er MA; Taha MO
    J Chem Inf Model; 2010 Sep; 50(9):1706-23. PubMed ID: 20831219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
    Abu Khalaf R; Abu Sheikha G; Bustanji Y; Taha MO
    Eur J Med Chem; 2010 Apr; 45(4):1598-617. PubMed ID: 20116902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new β-D-galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening.
    Abdula AM; Khalaf RA; Mubarak MS; Taha MO
    J Comput Chem; 2011 Feb; 32(3):463-82. PubMed ID: 20730780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
    Shahin R; Taha MO
    Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.
    Suaifan GA; Shehadehh M; Al-Ijel H; Taha MO
    J Mol Graph Model; 2012 Jul; 37():1-26. PubMed ID: 22609742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.
    Al-Nadaf A; Abu Sheikha G; Taha MO
    Bioorg Med Chem; 2010 May; 18(9):3088-115. PubMed ID: 20378363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling.
    Taha MO; Qandil AM; Zaki DD; AlDamen MA
    Eur J Med Chem; 2005 Jul; 40(7):701-27. PubMed ID: 15935905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
    Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
    J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new antifungal leads via pharmacophore modeling and QSAR analysis of fungal N-myristoyl transferase inhibitors followed by in silico screening.
    Taha MO; Qandil AM; Al-Haraznah T; Khalaf RA; Zalloum H; Al-Bakri AG
    Chem Biol Drug Des; 2011 Sep; 78(3):391-407. PubMed ID: 21679375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
    Al-Najjar BO; Wahab HA; Tengku Muhammad TS; Shu-Chien AC; Ahmad Noruddin NA; Taha MO
    Eur J Med Chem; 2011 Jun; 46(6):2513-29. PubMed ID: 21482446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
    Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
    J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of new β-D-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening.
    Abu Khalaf R; Abdula AM; Mubarak MS; Taha MO
    J Mol Model; 2011 Mar; 17(3):443-64. PubMed ID: 20490878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.